Embed Size (px)
Abstracts/Lung Cancer 13 (1995) 323-356 331
patients with pulmonary LELC previously reported in the literature similarly have been EBV-positive, whereas the four reported Caucasian patients all have been EBV-negative. Conclusion. Lymphcepithelioma- like carcinoma of lung occurring in Asians is an EBV- associated neoplasm: it also appears to occur at a higher frequency in Asians than Caucasians. It usually prcscnls as a solitary subpleural nodule, and there is no strong association with cigarette smoking. Most patients have early stage disease at presentation. From the limited available data, the behavior of LELC of lung is highly variable, ranging from apparent curability by excision (particularly for localized disease) to highly aggressive, extensive disease at presentation.
A case of malignant salivary gland type mixed tumor of the bronchus Nishimura H, Kawaguchi T, Miyazawa M, Ito M. Deportment of Swgery, Kofu City Hospital, Kofu. Jpn J Lung Cancer 1995;35:363-8.
A 69-year-old female complained of hemosputum. The chest X-ray film and CT showed a mass shadow in the right lower lobe (5’). Bronchoscopic examination revealed a tumor in the right B’. Primary lung carcinoma was suspected and right lower lobectomy with mediastinal lymph node dissection was performed. Histologically, the tumor, for the most part, consisted of myoepithelial cell nests and myxomatous stroma with glandular epithelial cells showed squamous cell metaplasia with partial malignant transformation consistent with differentiated squamous cell carcinoma. The tumor was diagnosed as malignant salivary gland type mixed tumor originating from the bronchial gland. The salivary gland type mixed tumor of the bronchus is extremely rare. To date, 20 cases have been reported in Japan, among which 7 cases were accompanied by malignant transformation.
Immunohistochemical study of adhesion molecules expressed on lung carcinoma cells: Its association with lymph node metastasis Odaka E, Takeuchi T, Sceda S, Ishii G, Mikata A, Yamaguchi Y. Department o/surgery, Institute ofMedicine, Chibo Universiv, Chibo. Jpn J Lung Cancer 1995;35:301-10.
Adhesion molecules were investigated in 48 cases of lung cancer, using an immunohistochemical technique. CD44, VIAlI 1 and ICAM- 1 were expressed in tumor cells, but other 8 adhesion molecules were largely absent. Adhesion molecules were present on the cell surface. CD44 and VLADl were detected in 33 (69%) cases, and ICAM-I was detected in 20 (42%) cases. The analysis of immunochemical data revealed that the positive cases for ant-CD44 mAb and ant-VLA81 mAb were significantly associated with lymph node metastasis (CD44: p<O.OOZ, VLAl31: p<O.OS). Positive findings for more than two mAbs showed even greater significant association. Our findings suggest that several adhesion molecules involving CD44 and VLADl play an important role in lymphatic metastasis.
Expression of the BCL-2 protein in normal and dysplastic bronchial epithelium and in lung carcinomas Walker C, Robertson L, Myskow M, Dixon G. Clatterbridge Cancer Research Trust, JK Douglas Cancer Research Lab., Clatterbridge Hospital, Bebington, Wirral L63 4JY. Br J Cancer 1995;72:164-9.
Although expression of the bcl-2 protein has been investigated in a number of non-haematological malignancies, little is known of its distribution in premalignant lesions. Expression of bcl-2 was invest- igated immunohistochemically in archival biopsies of normal (n = 8) and dysplastic bronchial epithelium (n = 56) and in 31 bronchial resection margins and their corresponding carcinomas. All dysplasias
had lost the prominent basal staining pattern seen in histologically normal epithelium. Two were negative and six had occasional basal positive cells. In 37 cases up to 66% of the epithelial cells throughout the full epithelial thickness were bcl-2 positive with weak to moderate staining intensity. In 11 cases, all severe dysplasias, strong expression was observed in > 90% of the epithelial cells. Four patterns of bcl-2 expression in dysplasias were identified and an increasingly aberrant pattern of bcl-2 expression correlated with an increasing grade of dysplasia (Spcarman’s rank correlation, P % 0.0001). Sixty-live per cent of the carcinomas contained bcl-2-positive cells. Patients with non- small-cell lung carcinomas (n = 27) in which > 50% ofthe tumour cells were bcl-2 positive showed a survival advantage compared with those with O-25% bcl-2-positive cells (P = 0.02). No correlation was found between ~53 expression and bcl-2 expression in dysplasias or carcinomas.
Parathyroid hormone-related protein antigen localization distinguishes between mesothelioma and adenocarcinoma of the lung Clark SF’, Chou ST, Martin TJ, Danks IA. St l4ncentk Inst. Medical Reseamh, II IktoriaParade, F&my, VIC. 3065. JPathol 1995;176:161- 5.
The distinction between pleural malignant mesothelioma and pulmonary adenocarcinoma remains a problem in diagnostic histo- pathology. Parathyroid hormone-related protein (PTHrP) has been demonstrated in the neoplastic cells of malignant mesotheliomata, using a polyclonal antiserum raised to synthetic PTHrP(l-16). In a series of 44 malignant mesotheliomata and 44 cases of pleural adenocarcinomata, PTHrP was localized immunohistochemically in 84 per cent of the mesotheliomata and in 11 per cent of the pleural adenocarcinomata. Normal and reactive mesothelium did not contain detectable PTHrP. The presence of PTHrP in a very high percentage of malignant mesotheliomata indicates the value of including it in the panel of antibodies utilized in the differential diagnosis of mesothelioma.
Localized adenocarcinoma of the lung: Oncogene expression of erbB-2 and p53 in 150 patients Harpole DH Jr, Marks JR, Richards WG, Hemdon JE II, Sugarbaker DJ. Division of Thoracic Surgery, Brigham and Women b Hospital, Harvard Medical School, 75 Francis Street, Boston. I.44 02115. Clin Cant Rcs 1995;1:659-64.
Historical information and pathological material from 150 conse- cutive patients with localized adenocarcinoma of the lung was collected to evaluate oncogene expression of erbB-2 and ~53, and erbB-2 gene amplification. Pathological material after resection was reviewed to verify histological staging, and patient follow-up was complete in all cases for at least 68 months. Immunohistochemistry of etbB-2 (HER-21 neu) and ~53 oncogene expression was performed on two separate pa&in tumor blocks for each patient with normal lung as control. Gene amplification of erbB-2 was measured after DNA extraction from 20-im sections of erbB-2-positive and -negative tumors. All analyses were blinded and included Kaplan-Meier survival estimates with Cox proportional hazards regression modeling. Two adequate blocks of tumor and normal lung were available for 138 (92%) patients. Immuno- histochemical identification of expression of ~53 was observed in 49 (37%) patients and erbB-2 in 17 (13%) patients. DNA dot blot analyses were performed on 17 erbB-2-positive and 13 randomly selected erbB- 2-negative tumors. There was 1(6%) of 17 erbB-2-positve tumors with 4-fold erbB-2 gene amplification. Actual 5-year survival was 63% and actuarial IO-year survival was 59% for the entire population of 150 patients. Significant univariate predictors (P < 0.05) of cancer death